Bacteriostatic Water · Research brief
BAC Water Volume for Tesamorelin and Ipamorelin: A 2026 Lab Guide (5mg, 10mg & 20mg Vials)
Short answer
The honest, complete answer is shorter than most pages make it: it is a concentration decision, the arithmetic is one division, and the number a study uses belongs in that study's own records. Everything below is that answer, in full. All compounds and diluents discussed are for laboratory research use only and not for human or veterinary consumption.
What volume of bacteriostatic water does a 5mg Tesamorelin vial take? The honest, complete answer is shorter than most pages make it: it is a concentration decision, the arithmetic is one division, and the number a study uses belongs in that study's own records. Everything below is that answer, in full. All compounds and diluents discussed are for laboratory research use only and not for human or veterinary consumption.
The Concentration Math for a 5mg Vial
The honest answer starts with how the arithmetic works: the 5mg of Tesamorelin in the vial is fixed, and the volume of bacteriostatic water a laboratory records determines only the resulting concentration. Concentration equals vial content divided by diluent volume — that relationship is the whole calculation, and it is where the math ends.
Which volume a given study records for a 5mg vial is a per-protocol documentation decision — published work varies by design, and the number belongs in that study's own records rather than on a supplier's page. The arithmetic itself is open: any vial content and any diluent volume produce exactly one concentration, and the calculator below computes and documents it for lab records.
The Research Solution Concentration Calculator computes and documents the resulting concentration for any vial-content and volume combination entered — it is the sanctioned home for concentration education, and everything it returns describes a solution on a lab bench. All compounds and diluents discussed here are for research use only and not for human or veterinary use.
BAC Water Volume for Tesamorelin: 5mg, 10mg and 20mg Vials
Two materials are involved, and the facts about each are short. The vial holds 5mg of Tesamorelin as a lyophilized research compound — a fixed mass that no diluent choice can change. Bacteriostatic water is sterile water containing 0.9% benzyl alcohol as a preservative; that composition is a label fact, and it is what distinguishes a multi-dose diluent from single-use sterile water in laboratory documentation. Which diluent a study uses, like every other parameter, is recorded in that study's own protocol. Both the compound and the diluent are supplied for laboratory research use only and are not for human or veterinary use.
What This Page Covers — and What It Deliberately Leaves Out
This page owns exactly one thing: the arithmetic between vial content, diluent volume, and concentration. It deliberately leaves out bench technique and material-care practice — those belong to institutional protocols and each product's own documentation (the COA and data sheet carry the lot-specific facts), not to a supplier's page. A research log that records vial content, diluent volume, and the resulting concentration has captured everything this page can responsibly contribute.
References
Peer-reviewed sources on Tesamorelin indexed in PubMed, listed for research context. Real Peptides supplies Tesamorelin for laboratory research use only.
- Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity research & clinical practice, 2026. PMID 41545261. doi:10.1016/j.orcp.2026.01.002
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 2011. PMID 21668043. doi:10.2165/11202240-000000000-00000
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. The Journal of infectious diseases, 2025. PMID 39813152. doi:10.1093/infdis/jiaf012
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (London, England), 2024. PMID 38905488. doi:10.1097/QAD.0000000000003965
- Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of clinical and translational science, 2023. PMID 36845310. doi:10.1017/cts.2022.515
- Tesamorelin improves fat quality independent of changes in fat quantity. AIDS (London, England), 2021. PMID 33756511. doi:10.1097/QAD.0000000000002897
- Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific reports, 2021. PMID 34006921. doi:10.1038/s41598-021-89966-y
- Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI insight, 2020. PMID 32701508. doi:10.1172/jci.insight.140134
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA